KRAS and non-small cell lung carcinoma: Drugs targeting KRAS are being developed, with the example of KRAS (G12C) inhibitors, which led to FDA approval of sotorasib in 2021and adagrasib in 2022 (63) for patients with KRAS-mutated non-small cell lung cancer (NSCLC) (64).